Last reviewed · How we verify
NCT07400393: MCSP
Healey ALS MyMatch Common Screening Protocol
trial in ALS in 500 participants. Not yet recruiting.
16 March 2029
Quick facts
| Lead sponsor | Massachusetts General Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 16 March 2026 |
| Primary completion | 16 March 2029 |
| Estimated completion | 16 March 2029 |
Conditions studied
- ALS — all drugs for ALS →
- ALS (Amyotrophic Lateral Sclerosis) — all drugs for ALS (Amyotrophic Lateral Sclerosis) →
- ALS - Amyotrophic Lateral Sclerosis — all drugs for ALS - Amyotrophic Lateral Sclerosis →
Sponsor
Massachusetts General Hospital
Who can join
18 and older, any sex, with ALS or ALS (Amyotrophic Lateral Sclerosis). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of the Healey ALS MyMatch Common Screening Protocol (MCSP), an observational study, is to identify individuals with ALS who may be eligible to be matched to a currently enrolling ALS MyMatch trial. Participants will complete a MCSP Screening Visit and undergo clinical assessments, laboratory testing, and biomarker analyses to determine preliminary trial eligibility. The study also characterizes clinical, genetic, and biofluid biomarker profiles, assesses the prevalence of ALS-associated gene variants, and banks blood samples for future ALS and biomarker research. MCSP enables simultaneous screening for multiple trial-specific biomarkers and uses a targeted medical history form to optimize matching of participants to appropriate MyMatch trials.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07400393
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ALS
Currently open trials in the same condition.
- NCT07460037 — Chinese-Specific Speech Imagery Coding Using High-Density ECoG · NA · recruiting
- NCT07006571 — At-home Treatment With Cortico-spinal tDCS for Amyotrophic Lateral Sclerosis · NA · recruiting
- NCT07193953 — Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) · Phase 1 · recruiting
- NCT06735014 — Multicenter ALS Imaging Study · recruiting
- NCT06511934 — Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Tablet-01) · NA · recruiting
Other Massachusetts General Hospital trials
Trials by the same sponsor.
- NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
- NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
- NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
- NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
- NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07400393 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
- Last refreshed: 10 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07400393.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing